ARIAD Pharmaceuticals, Inc. (ARIA) announced long-term durability-of-response data from its Phase 1 trial of Iclusig (ponatinib) in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia, or CML, or Philadelphia chromosome-positive acute lymphoblastic leukemia, or Ph+ ALL.
The study showed that among chronic-phase, or CP, patients, the median durations of major and complete cytogenetic responses, along with major molecular response, have yet to be reached. The median follow-up for CP patients still on study is now more than three years.
These data will highlighted in a presentation at the Annual Meeting of the American Society of Clinical Oncology being held in Chicago.
Michael Mauro, associate professor at the Oregon Health & Science University, Portland, Oregon, said, "These data show that ponatinib continues to provide deep, durable clinical responses in chronic-phase CML patients who failed several prior tyrosine kinase inhibitor therapies. It is noteworthy that these patients are maintaining their responses over this long period of time and that a median duration of response to ponatinib has not yet been reached."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.